药品行业周报2026.3.9-2026.3.13：十五五规划：深化医保支付方式改革，鼓励商业保险协同支付-20260315

Investment Rating - The report assigns a "Buy" rating to the pharmaceutical industry, indicating a positive outlook for the next 6-12 months [5][60]. Core Insights - The "14th Five-Year Plan" positions biomedicine as a strategic emerging industry, creating unprecedented opportunities for the pharmaceutical sector. The plan emphasizes a comprehensive support system for the entire chain from research and development to payment and usage, which is expected to accelerate the approval and market entry of innovative drugs [4][59]. - The integration of AI with biomedicine is transitioning from concept to industrialization, promising a revolution in drug discovery and development efficiency [5][60]. Summary by Sections Market Review - The A-share biotechnology sector declined by 1.26%, while the chemical preparation sector fell by 0.82%. The Hang Seng Healthcare index dropped by 3.11%, ranking as the 10th largest decline among major sectors [1][9]. Industry Dynamics and Important Announcements - The recent government announcement highlights the inclusion of biomedicine in the strategic emerging industries, with a focus on optimizing the approval process for innovative drugs and reforming medical insurance payment methods to enhance accessibility [3][58]. Investment Recommendations - The report emphasizes that companies capable of commercializing leading products overseas and demonstrating continuous innovation will be favored in the market. The focus is on the quality of licensing agreements and the robustness of clinical data [5][60].